AbbVie Inc (ABBV)vsExelixis Inc (EXEL)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
EXEL
Exelixis Inc
$52.49
-0.69%
HEALTHCARE · Cap: $13.35B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2544% more annual revenue ($62.82B vs $2.38B). EXEL leads profitability with a 35.1% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.59. EXEL earns a higher WallStSmart Score of 72/100 (B).
ABBV
Buy63
out of 100
Grade: C+
EXEL
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+67.2%
Fair Value
$161.90
Current Price
$52.49
$109.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Every $100 of equity generates 43 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 41.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : EXEL
The strongest argument for EXEL centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.1% and operating margin at 41.1%.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : EXEL
The primary concerns for EXEL are PEG Ratio.
Key Dynamics to Monitor
ABBV profiles as a value stock while EXEL is a mature play — different risk/reward profiles.
EXEL carries more volatility with a beta of 0.43 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
EXEL scores higher overall (72/100 vs 63/100), backed by strong 35.1% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Exelixis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?